{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:05:10Z","timestamp":1761491110250,"version":"3.41.2"},"reference-count":26,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001862","name":"The Swedish Research Council","doi-asserted-by":"crossref","award":["2015-02561","2019-01112"],"award-info":[{"award-number":["2015-02561","2019-01112"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LUA\/ALF","award":["ALFGBG-719531"],"award-info":[{"award-number":["ALFGBG-719531"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Pharmacokinetic properties of cortisone acetate (CA) and hydrocortisone (HC) differ because CA needs to be converted into cortisol to become active.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This work analyzed the metabolic consequences of switching CA to an equivalent daily dose of HC in patients with secondary adrenal insufficiency (SAI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This was a post hoc analysis from a prospective study including individuals with hypopituitarism receiving growth hormone replacement. Data were collected before and after a switch from CA to an equivalent dose of HC (switch group). Two control groups were included: patients continuing CA replacement (CA control group) and adrenal-sufficient hypopituitary patients (AS control group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis included 229 patients: 105, 31, and 93 in the switch, CA control, and AS control groups, respectively. After the change from CA to HC, increases in mean body weight (1.2 kg; P\u2005&amp;lt;\u2005.05), waist circumference (2.9 cm; P\u2005&amp;lt;\u2005.001), body fat measured by dual-energy x-ray absorptiometry (1.3 kg; P\u2005&amp;lt;\u2005.001), and glycated hemoglobin (0.3%; P\u2005&amp;lt;\u2005.05) were recorded in the switch group. The increase in mean waist circumference was greater than in the AS control group (0.9 cm; P\u2005&amp;lt;\u2005.05). Mean body fat increased in the switch group but not in the CA control group (\u20130.7 kg; P\u2005&amp;lt;\u2005.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A switch from CA to an equivalent dose of HC was associated with a worsened metabolic profile, suggesting that HC has a more powerful metabolic action than CA based on the assumption that 20 mg HC equals 25 mg CA.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jendso\/bvaa160","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T16:22:23Z","timestamp":1603988543000},"source":"Crossref","is-referenced-by-count":6,"title":["Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency"],"prefix":"10.1210","volume":"4","author":[{"given":"Elise","family":"Ekstrand","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Primary Care Facility Kusten, Ytterby, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-2071","authenticated-orcid":false,"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0204-9492","authenticated-orcid":false,"given":"Oskar","family":"Ragnarsson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rgen","family":"Isgaard","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-8440","authenticated-orcid":false,"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"2020120503170736200_CIT0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6823-12-8","article-title":"Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency\u2014a worldwide patient survey","volume":"12","author":"Forss","year":"2012","journal-title":"BMC Endocr Disord."},{"issue":"10","key":"2020120503170736200_CIT0002","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2020120503170736200_CIT0003","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1210\/jc.2016-2216","article-title":"Effects of hydrocortisone on the regulation of blood pressure: results from a randomized controlled trial","volume":"101","author":"Werumeus Buning","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2020120503170736200_CIT0004","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"4758","key":"2020120503170736200_CIT0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/bmj.1.4758.559","article-title":"Antirheumatic effects of hydrocortisone (free alcohol), hydrocortisone acetate, and cortisone (free alcohol) as compared with cortisone acetate; results from oral administration in patients with rheumatoid arthritis","volume":"1","author":"Boland","year":"1952","journal-title":"Br Med J."},{"issue":"6","key":"2020120503170736200_CIT0006","first-page":"417","article-title":"16a-Methyl corticosteroids; a new series of anti-inflammatory compounds; clinical appraisal of their antirheumatic potencies","volume":"88","author":"Boland","year":"1958","journal-title":"Calif Med."},{"key":"2020120503170736200_CIT0007","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cpt196125615","article-title":"Clinical pharmacology of the anti-inflammatory steroids","volume":"2","author":"Liddle","year":"1961","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"2020120503170736200_CIT0008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1749-6632.1955.tb42485.x","article-title":"Metabolic effects of metacortandralone and metacortandracin","volume":"61","author":"Bunim","year":"1955","journal-title":"Ann N Y Acad Sci."},{"issue":"5","key":"2020120503170736200_CIT0009","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1210\/jc.2002-020901","article-title":"Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength","volume":"88","author":"Svensson","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2020120503170736200_CIT0010","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1210\/jcem.86.10.7887","article-title":"A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices","volume":"86","author":"G\u00f6therstr\u00f6m","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2020120503170736200_CIT0011","first-page":"2865","article-title":"Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency","volume":"81","author":"Johannsson","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2020120503170736200_CIT0012","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem."},{"issue":"4","key":"2020120503170736200_CIT0013","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/eje.1.02118","article-title":"Body composition during GH replacement in adults\u2014methodological variations with respect to gender","volume":"154","author":"Koranyi","year":"2006","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2020120503170736200_CIT0014","doi-asserted-by":"crossref","first-page":"E1938","DOI":"10.1210\/jc.2012-2432","article-title":"Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma","volume":"97","author":"Zueger","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2020120503170736200_CIT0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/EJE-17-0340","article-title":"Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma","volume":"177","author":"Hammarstrand","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2020120503170736200_CIT0016","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2265.1995.tb02928.x","article-title":"Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism","volume":"43","author":"Dunne","year":"1995","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2020120503170736200_CIT0017","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/S0004-27302004000500017","article-title":"One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency","volume":"48","author":"Caldato","year":"2004","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"3","key":"2020120503170736200_CIT0018","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1210\/jcem-55-3-551","article-title":"Steroid replacement in Addison\u2019s disease and in subjects adrenalectomized for Cushing\u2019s disease: comparison of various glucocorticoids","volume":"55","author":"Khalid","year":"1982","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2020120503170736200_CIT0019","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1365-2265.2003.01860.x","article-title":"The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency","volume":"59","author":"Suliman","year":"2003","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"2020120503170736200_CIT0020","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2020120503170736200_CIT0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2125.1984.tb04999.x","article-title":"Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability","volume":"17","author":"Heazelwood","year":"1984","journal-title":"Br J Clin Pharmacol."},{"issue":"5546","key":"2020120503170736200_CIT0022","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bmj.2.5546.205","article-title":"Conversion of cortisone to cortisol and prednisone to prednisolone","volume":"2","author":"Jenkins","year":"1967","journal-title":"Br Med J."},{"issue":"5","key":"2020120503170736200_CIT0023","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur J Endocrinol."},{"key":"2020120503170736200_CIT0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000360556","article-title":"Cardiovascular and metabolic impact of glucocorticoid replacement therapy","volume":"43","author":"Johannsson","year":"2014","journal-title":"Front Horm Res."},{"issue":"2","key":"2020120503170736200_CIT0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12020-020-02458-3","article-title":"Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia","volume":"70","author":"Esposito","year":"2020","journal-title":"Endocrine."},{"issue":"7","key":"2020120503170736200_CIT0026","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/eci.12770","article-title":"Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on HDL","volume":"47","author":"Werumeus Buning","year":"2017","journal-title":"Eur J Clin Invest."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaa160\/34053853\/bvaa160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/12\/bvaa160\/34713961\/bvaa160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/12\/bvaa160\/34713961\/bvaa160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T14:55:44Z","timestamp":1669388144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaa160\/5943029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaa160","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,29]]},"article-number":"bvaa160"}}